Our Vision
Let’s make the world a better place, one breath at a time
About ASG
Asia Scientific Global (“ASG”) is an innovative pharmaceutical company specializing in the development of new inhalation drugs. It was founded in 2022 with a team of outstanding talents that include by one of the world’s top respiratory R&D team along with seasoned patent and finance professionals. The company is committed to developing high value new inhalation drugs. In addition to its current laboratory in Taiwan, ASG also plans to set up a laboratory in Singapore. It also has plans to build out additional regional teams in Asia and North America for product research and development, clinical trials and market development. ASG will leverage Asia as its R&D home base and aims for the global market with its products portfolio.
ASG is an inhalation drug-focused platform company established based on its proprietary Aero-Particles Process Control (“aPPC”) Technology, formulation developments, and special medical device development as its core advantages. By targeting the development of dry powder inhalation (“DPI”) absorbed through the respiratory tract as 505(b)(2) new dosage forms and new drugs, we develop breakthrough new drugs via our design to improve the therapeutic effects of existing drugs and reduce side effects. Through precise indication selections and market analysis, ASG targets the unmet needs of the medical market and strategically cooperates with the world's leading multinational medical research centers and CDMOs across all facets, from drug research and development, trial production, pilot production, clinical trials and commercial production, so that our products can successfully enter the market. We are confident that our uniquely designed special dosage forms can provide the best-in-class medical solutions that are faster, more effective, safer and more convenient for patients around the world.
ASG is working on its own artificial intelligence system and development technology to quickly complete the patent layout. With a more flexible and cost-effective business model, ASG can accelerate the process of drug screening and development, enter into pre-clinical tests and clinical trials, and ultimately secures drug certification and product launches to reach more patients to deliver on its mission statement of “Let’s make the world a better place, one breath at a time”.
ASG Global Operation
ASG is targeting the global medical market. In addition to currently having laboratories in Taiwan, ASG has also planned to establish laboratories in Singapore and Beijing. It has strategically cooperated with the world's leading multinational medical research centers and well-known CDMOs.
Hugues Hung
Chief Executive Officer
Mr. Hung has more than 20 years of diverse entrepreneurial and business experiences in both Taiwan and mainland China.
Mr. Hung was the co-founder of Cayennetech Entertainment (紅心辣椒, 4946) in 2006. After successfully exiting the business, Mr. Hung founded several ventures (including Hugues’ Vision Optical Inc.) and eventually joined Synmosa Biopharm (健喬信元, 4114) as the Special Assistant to Chairman. Mr. Hung later assumed the Manufacturing Site Director of Intech Biopharm (益得生技, 6461) to focus on building the pharmaceutical factory site. After completing the construction and qualification of the factory site, Mr. Hung led the team to successfully complete two site inspection by Taiwan FDA. In 2021, Mr. Hung assumed the role of Chief Financial Officer of Intech Biopharm and raised NTD300m for the company before departing to establish ASG Inspiration Laboratory Limited.
Mr. Hung has a Bachelor of Science degree from Babson College in Boston, MA. Mr. Hung also holds a joint MBA degree from Fudan University in Shanghai, China, and Massachusetts Institute of Technology in Boston, MA.
Dr. Alex Yu
Chief Science Officer
With over 12 years of experience in drug research and design of biopharmaceuticals, Dr. Yu has a specialty focus in the development of metered dose and dry powder inhalers. He is proficient in various pharmaceutical technologies and application problems and has a proven track record of successfully bringing products to market.
In addition, he has extensive knowledge on small to industrialized batch drug production process, and he has numerous experiences solving problems in the scale-up of pharmaceutical processes. Dr. Yu is familiar with various policies and regulations of drugs in Taiwan, China, Europe and the U.S. and their respective analytical methods development and new drug application requirements.
Dr. Yu has a Ph.D. degree from National Taiwan University Institute of Pharmacy with major in Pharmacy and Molecular Pharmacy.
Johnson Lee
Chief Operating Officer
Mr. Lee brings over 30 years of experience in operation management and senior leadership positions at both listed and private companies. Prior to joining ASG, Mr. Lee served as CEO and COO for Crowdinsight Corporation from 2019 to 2021 and had served as consultant for Liteon Corporation from 2015 to 2018.
He is responsible for the more than 30 inventions and patents on artificial intelligence, IOT system integration, and streetlight improvement design.
Earlier in his career, he worked with Carry Computer and then Meiloon Industrial Co. Paradigm Electronic and Wistron in several product and manufacturing management leadership positions, including Strategic Alliance management and Sales Integration.
Mr. Lee holds a Master of Science degree from the University of Michigan and a Bachelor of Science degree from National Taiwan University.
Mr. Hung has more than 20 years of diverse entrepreneurial and business experiences in both Taiwan and mainland China.
Mr. Hung was the co-founder of Cayennetech Entertainment in 2006. After successfully exiting the business, Mr. Hung founded several ventures (including Hugues’ Vision Optical Inc.) and eventually joined Synmosa Biopharm as the Special Assistant to Chairman. Mr. Hung later assumed the Manufacturing Site Director of Intech Biopharm to focus on building the pharmaceutical factory site. After completing the construction and qualification of the factory site, Mr. Hung led the team to successfully complete two site inspection by Taiwan FDA. In 2021, Mr. Hung assumed the role of Chief Financial Officer of Intech Biopharm and raised NTD300m for the company before departing to establish ASG Inspiration Laboratory Limited.
Mr. Hung has a Bachelor of Science degree from Babson College in Boston, MA. Mr. Hung also holds a joint MBA degree from Fudan University in Shanghai, China, and Massachusetts Institute of Technology in Boston, MA.
Our Team
Patrick Chao
Chief Financial Officer
Mr. Chao has over 15 years of combined experience in corporate finance and startups spanning across various industries in the Asia Pacific region with an emphasis in Hong Kong and China. He carries expertise in a wide range of public and private transactions, including mergers and acquisitions, corporate restructuring, initial public offers, as well as other forms of equity and debt investments.
Prior to joining ASG, he served as the country manager of an e-commerce aggregator Una Brands in Taiwan and was responsible for its market assessment and acquisitions. He was a strategic adviser for a boutique fitness venture as well.
Mr. Chao holds both Master of Business Administration and Bachelor of Science degrees from Leonard N. Stern School of Business at New York University.
Goh Yong Keng
Chief Project Officer
Mr. GOH has over 45+ years of engineering experience with 35+ years in Biomedical industry at Plant Director or Director of Engineering position. Mr. Goh specializes in design, build, qualified and operate pharmaceuticals projects to commercial manufacturing. He worked with Merck, GSK, Roche, and other large multinational pharma companies at over 15 projects including six aseptic and sterile facilities that all are HAS, TFDA, TGA, FDA and EU approved facilities. With Expertise in design and construction of Biopharma facility, Mr. Goh has also been invited as the consultant for the major pharma facilities design, including Aseptic Cytotoxin and Gene Therapy Facilities in Taiwan and USA.
Peter Huang
Chemistry, Manufacturing & Controls Director
Mr. Huang has over 10 years of management and research experience in the pharmaceutical industry. He brings expertise in facility design and innovation, production/project/technology transfer management, process improvement/development, product formulation, and analytical method development.
Before joining ASG, he was a plant director of a pharmaceutical factory and also worked as a value stream manager in an international pharmaceutical company, responsible for the pharmaceutical factory of anti-cancer drugs.
Mr. Huang holds a MS degree from the Natural Products Research Institute of Kaohsiung Medical University and a BS degree in Chemistry (minor in Life Science) from Fu Jen Catholic University.